Acute kidney injury biomarkers
Biomarkers to detect and predict acute kidney injury.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 49, 52, 59, 68, 104.
New guidelines and consensus this year
- Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney Int2026 Jun
- Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceJACC Heart Fail2026 Apr
All papers from the last 12 months
910 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Electrochemical immunosensors for KIM-1 and NGAL: recent advances toward early and point-of-care diagnosis of acute kidney injuryClin Chim Acta2027 Feb 15PMID 42679883Review
- Diagnostic pitfall: NSAID-induced membranous nephropathy with PLA2R positivity, IgG1-predominant deposits, C1q positivity, and concurrent acute interstitial nephritis-A case reportClin Chim Acta2027 Feb 15PMID 42503368
- Lactate in acute kidney injury: pathobiology, risk stratification, and clinical interpretationRen Fail2026 DecPMID 42802082Review
- Occupational heatstroke-induced acute kidney injury: a narrative review of mechanisms, biomarkers, and the timing of blood purification initiationRen Fail2026 DecPMID 42734065Review
- Diagnostic and prognostic value of fibroblast growth factor 23 in acute kidney injury: systematic review and meta-analysisRen Fail2026 DecPMID 42693098Meta-analysisSystematic review
- Integrated biomarker analysis of multi-organ effects following MDMA and alcohol co-consumption in Pakistan: A pilot studyToxicol Rep2026 DecPMID 42620295
- Association of transglutaminase-2 with contrast-induced acute kidney injury in Chinese patients with acute coronary syndrome: a prospective cohort studyAnn Med2026 DecPMID 42573605
- Novel biomarkers for acute kidney injury in high-risk pediatric populations: a systematic reviewRen Fail2026 DecPMID 42448446Systematic review
- Urinary neutrophil gelatinase-associated lipocalin: a key biomarker for differentiating acute kidney injury and predicting short-term mortality in liver cirrhosis patientsRen Fail2026 DecPMID 42409784
- A four-gene signature for diagnosis of acute kidney injury following kidney transplantationRen Fail2026 DecPMID 42315974
More nephrology trends
All specialties →GLP-1 drugs in kidney disease
GLP-1 based medicines and kidney outcomes.
Key point: In CKD, GLP-1 receptor agonists were associated with fewer major adverse kidney events and lower albuminuria, primarily in type 2 diabetes, with gastrointestinal concerns.
SGLT2 inhibitors in CKD
SGLT2 inhibitors to slow chronic kidney disease.
Key point: In non-diabetic CKD, renin-angiotensin system inhibitors and SGLT2 inhibitors would be indicated as the treatment of choice.
IgA nephropathy
IgA nephropathy and the new targeted treatments being studied.
Lupus nephritis
Kidney involvement in lupus and its newer treatments.
Key point: Lupus nephritis management is increasingly individualized, with expanding treatment options, combination therapy, and a trend toward lower corticosteroid doses.
Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"acute kidney injury"[tiab] AND biomarker*[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.